Madrigal Pharmaceuticals (NASDAQ: MDGL)
Madrigal Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Madrigal Pharmaceuticals Company Info
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
News & Analysis
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
There's a bright future ahead for this company.
Is Madrigal Pharmaceuticals Stock a Buy?
The biotech could be worth a lot more in 10 years.
This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock
One player's minor pain is another's moderate gain.
Is It Too Late to Buy Madrigal Pharmaceuticals Stock?
Will being the first to its market ensure that its future is bright?
Is Madrigal Pharmaceuticals a Millionaire Maker?
Its revenue ramp-up is just starting, and its market looks lucrative.
Is Madrigal Pharmaceuticals Stock a Buy?
The company could become a prominent player in the biotech industry, but that might take a while.
Where Will Madrigal Pharmaceuticals Be in 3 Years?
The coast is clear for it to grow, for now.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.